Publications
April 17, 2020
Journal of Biological Chemistry
Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
March 25, 2020
Science Translational Medicine
Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
July 26, 2019
SLAS Discovery
A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation
Posters
November 2020
Society for Immunotherapy of Cancer's (SITC) Annual Meeting
DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor, in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone
September 2020
World Muscle Society
Clinical Development of SRK-015,a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy
September 2020
World Muscle Society
Myostatin Dynamics in Health and Disease: Pharmacologic Effects of SRK-015, a Highly Selective Monoclonal Antibody Inhibitor of Myostatin Activation